MLH1 and cancer: Based on these findings, full germline genetic testing should be offered to every new MSI-H/dMMR cancer diagnosis—excluding those who show BRAF V600E somatic PV and/or hypermethylation of the MLH1 promoter—and to families who display high clinical risk [116].